05.31.26 -- Dealing With Emerging Data Sovereignty Regulations

This weekend’s selections from Life Science Leader offer insights — in three different contexts — into how the collection, management, and use cases for patient data are changing. Data silos are returning, by necessity, due to emerging regulations in global markets that use the European Union’s GDPR as merely a starting point. Data sovereignity has become a board-level topic, with an operational response.

Patient data is critical, however it’s collected and managed, but it can only get you so far, writes Cognition Therapeutics president and CEO Lisa Ricciardi. There is no substitute for genuine, authentic dialogue; when patients become more than just datasets, anecdotes become actionable.

On the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about using a suspicion index, EHR and claims data – analyzed by AI models – to help identify and diagnose patients with Niemann Pick Type C.

Check out a curated selection from our partners, below, and thanks as always for reading.

Ben Comer             
Chief Editor, Life Science Leader

Southern Star Research shows how early-phase trials generate more meaningful patient data when diverse healthy populations are included from the start.

Eurofins PSS Insourcing Solutions demonstrates how smarter sample and data workflows break silos, improving visibility, compliance, and operational decision-making.

Ergomed Clinical Research explains why inclusive trial design produces higher-quality data, faster enrollment, and stronger regulatory confidence across programs.

20/20 Onsite reveals how point-of-need patient engagement reduces ophthalmology trial dropout, protecting data integrity and study timelines.

CSS explores how AI, digital health, and patient-first design are reshaping recruitment data into precise, actionable enrollment strategies.

Mural Health highlights how supporting global trial participants transforms logistical data into trust, retention, and more reliable outcomes.

Worldwide Flex examines how AI and open-source tools are redefining biostatistics, changing how patient data is analyzed, shared, and scaled.